Puridify
Develops purification solutions for biotherapeutics.
| GBP | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | (15 %) | (70 %) | (8854 %) | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (749 %) | (1936 %) | (10215 %) | 88 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (409 %) | (2131 %) | (10802 %) | 100 % | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 198 % | 452 % | 1312 % | (18 %) | - | - |
Source: Company filings or news article
Related Content
Puridify is a startup focused on revolutionizing the bioprocessing industry, specifically targeting the manufacturing of industrial biomolecules. The company develops advanced purification technologies that enhance the production of biotherapeutics—medicines derived from biological sources. These technologies are designed to improve the efficiency, cost-effectiveness, and reliability of manufacturing processes.
Puridify primarily serves clients in the biopharmaceutical sector, which includes companies that develop and produce drugs and therapies based on biological molecules. This market is crucial for the development of treatments for various diseases, including cancer, autoimmune disorders, and infectious diseases.
The business operates within the bioprocessing market, a niche segment of the broader biotechnology and pharmaceutical industries. This market is characterized by the need for highly specialized technologies and processes to produce complex biological products.
Puridify's business model revolves around the development and commercialization of its proprietary purification technologies. The company generates revenue by selling these technologies to biopharmaceutical companies, which integrate them into their manufacturing processes. Additionally, Puridify may offer consulting services to help clients optimize the use of their technologies, further enhancing their revenue streams.
In summary, Puridify is a key player in the bioprocessing industry, providing innovative solutions that improve the production of biotherapeutics. By serving biopharmaceutical companies, the startup contributes to the advancement of medical treatments and therapies.
Keywords: bioprocessing, biomolecules, biotherapeutics, purification technologies, biopharmaceutical, manufacturing, efficiency, cost-effective, reliability, biotechnology.